RESEARCH TRIANGLE PARK – BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has a new member of its leadership team: Jinky Ang Rosselli, who will be the company’s chief data and insights officer.
In a statement, the company indicated this was a new role. Rosselli joined BioCryst in 2015 as the vice president of global business analysis and operations. Now, according to a company statement, Rosselli will lead “a global team to leverage and build the company’s data science, analytics and insights infrastructure, helping inform strategic decision making.” Rosselli will join the BioCryst leadership team and report directly to Jon Stonehouse, chief executive officer of BioCryst.
“Jinky’s ability to employ traditional and non-traditional methods to insight gathering, evidence generation and data science has proven to be a critical competitive advantage for BioCryst,” said Stonehouse in a statement.
Rosselli previously led the global business intelligence and insight team at United Therapeutics and has also worked at Talecris Biotherapeutics (which is now Grifols) and at Novartis.
“BioCryst’s rigorous, no-fear approach to data and insights truly differentiates us as a company,” said Rosselli in a statement. “We are not only fully anchored in the integrity of data, but believe strongly in the importance of humanizing data in the right context, a truly holistic approach.”
Earlier this year, the company withdrew its plans for a $200 million stock offering. At the time, the company released a statement that indicated the company believed it was well-capitalized and would have cash, cash equivalents, restricted cash, and investments of $222.8 million as of June 30, along with an option to access an additional $75 million from an existing credit facility, noting “we believe our current cash runway takes us into 2023.”
